Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Ascorbic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB known ✓ | P10828 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.66 |
| ▸ | MAPT | P10636 | 2/20 | 0.66 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.66 |
| ▸ | TYR | P14679 | 2/20 | 0.41 |
| ▸ | MANBA | O00462 | 1/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.36 |
| ▸ | HSPE1 | P61604 | 1/20 | 0.36 |
| ▸ | TST | Q16762 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | BLM | P54132 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ascorbic Acid SCHEMBL29351212 | 1.00 | LMNA (0.66) | LMNAMAPTL3MBTL1TYRMANBA | |
| Ascorbic Acid SCHEMBL17141722 | 1.00 | LMNA (0.66) | LMNAMAPTL3MBTL1TYRMANBA | |
| Ascorbic Acid SCHEMBL29598547 | 1.00 | LMNA (0.66) | LMNAMAPTL3MBTL1TYRMANBA | |
| Ascorbic Acid SCHEMBL3745 | 1.00 | LMNA (0.66) | LMNAMAPTL3MBTL1TYRMANBA | |
| Ascorbic Acid SCHEMBL19378674 | 1.00 | LMNA (0.66) | LMNAMAPTL3MBTL1TYRMANBA | |
| Ascorbic Acid SCHEMBL30301317 | 1.00 | LMNA (0.66) | LMNAMAPTL3MBTL1TYRMANBA | |
| Ascorbic Acid SCHEMBL29350598 | 1.00 | LMNA (0.66) | LMNAMAPTL3MBTL1TYRMANBA | |
| Ascorbic Acid SCHEMBL20839746 | 1.00 | LMNA (0.66) | LMNAMAPTL3MBTL1TYRMANBA | |
| Ascorbic Acid SCHEMBL20788532 | 1.00 | LMNA (0.66) | LMNAMAPTL3MBTL1TYRMANBA | |
| Ascorbic Acid SCHEMBL31277061 | 0.98 | LMNA (0.64) | LMNAMAPTL3MBTL1TYRMANBA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114947039-A | Compound anticorrosive composition based on L-amino acid polyglycoside, and preparation method and application thereof | 绥化市蓝源生物工程有限公司 | 2022-08-30 | — | — | CN | claimed |
| US-12485129-B2 | Water soluble compositions comprising purified cannabinoids | CANOPY GROWTH CORPORATION (CA) | 2025-12-02 | — | — | US | disclosed |
| CN-119798562-A | Polymer dispersing agent for paint and preparation method thereof | 科之杰新材料集团有限公司 | 2025-04-11 | — | — | CN | disclosed |
| WO-2025076285-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME | DELPHIA THERAPEUTICS, INC. (US) | 2025-04-10 | — | — | WO | disclosed |
| US-20240261445-A1 | PRECISION RADIOPHARMACEUTICAL THERAPY OF LYMPHOMA AND OTHER DISEASES | WASHINGTON UNIVERSITY (US) | 2024-08-08 | — | — | US | disclosed |
| CN-117279620-A | Functionalized biocatalytic compositions | 佩尔西奥制药公司 | 2023-12-22 | — | — | CN | disclosed |
| CN-114947039-A | Compound anticorrosive composition based on L-amino acid polyglycoside, and preparation method and application thereof | 绥化市蓝源生物工程有限公司 | 2022-08-30 | — | — | CN | disclosed |
| CN-114947039-A | Compound anticorrosive composition based on L-amino acid polyglycoside, and preparation method and application thereof | 绥化市蓝源生物工程有限公司 | 2022-08-30 | — | — | CN | disclosed |
| EP-3694477-A1 | TOPICAL PRODUCTS WITH A BIPHASIC SYSTEM | Cmed Aesthetics S.r.l. (IT) | 2020-08-19 | — | — | EP | disclosed |
| WO-2019058249-A1 | TOPICAL PRODUCTS WITH A BIPHASIC SYSTEM | CMED AESTHETICS S.R.L. (IT) | 2019-03-28 | — | — | WO | disclosed |
| EP-1768500-A1 | COMPOSITIONS SUITABLE FOR TREATING CUTANEOUS SIGNS OF AGING | Ferrosan A/S (DK) | 2007-04-04 | — | — | EP | disclosed |
| WO-2006000226-A1 | COMPOSITIONS SUITABLE FOR TREATING CUTANEOUS SIGNS OF AGING | FERROSAN A/S (DK) | 2006-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12485129-B2 | Water soluble compositions comprising purified cannabinoids | CNR2, CNR1, PTGES | THRB 3365/4885LMNA 2955/4885MAPT 1609/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.